Epysqli is used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia ...

EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, ...

Teva Pharmaceuticals (TEVA) and Samsung Bioepis (SSNLF) announced the availability of EPYSQLI in the U.S. EPYSQLI is a biosimilar to Soliris ...

EPYSQLI is designed to treat gMG in adults who are anti-acetylcholine receptor antibody positive.

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome ...

KLP Kapitalforvaltning AS purchased a new position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund purchased 10,800 shares of ...

Sanofi's decision to end development of the drug in myasthenia gravis may lie in the changing landscape of therapies for the disease, including the approval of Argenx' neonatal FC receptor (FcRn ...

FineHeart S.A., a clinical-stage medtech company developing breakthrough solutions for cardiology, announces the appointment of Sébastien Robitaille as Chief Financial Officer. Driven by the ...

Like Soliris and Ultomiris, Zilbrysq is approved for use in adults with gMG who are anti-acetylcholine receptor (AChR ... and chief executive of the Myasthenia Gravis Foundation of America.

The Chan Zuckerberg Biohub New York (CZ Biohub NY) today announced nine new investigators to its growing roster of talented ...

Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...